People: Astex Pharmaceuticals Inc (ASTX.OQ)
ASTX.OQ on NASDAQ Stock Exchange Global Select Market
5.54USD
4:00pm EDT
5.54USD
4:00pm EDT
Price Change (% chg)
$0.31 (+5.93%)
$0.31 (+5.93%)
Prev Close
$5.23
$5.23
Open
$5.35
$5.35
Day's High
$5.59
$5.59
Day's Low
$5.28
$5.28
Volume
273,853
273,853
Avg. Vol
394,279
394,279
52-wk High
$6.94
$6.94
52-wk Low
$2.15
$2.15
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
James Manuso |
64 | 2011 | Chairman of the Board, Chief Executive Officer |
Harren Jhoti |
50 | 2011 | President, Director |
Peter Fellner |
70 | 2011 | Independent Vice Chairman of the Board |
Michael Molkentin |
58 | 2003 | Chief Financial Officer, Corporate Secretary |
Mohammad Azab |
2009 | Chief Medical Officer | |
Martin Buckland |
58 | 2011 | Chief Business Officer |
Walter Lack |
65 | 2012 | Lead Independent Director |
Charles Casamento |
67 | 2007 | Independent Director |
Thomas Girardi |
73 | 2000 | Independent Director |
Allan Goldberg |
71 | 2005 | Independent Director |
Timothy Haines |
55 | 2011 | Independent Director |
Ismail Kola |
56 | 2011 | Independent Director |
Susanna Chau |
Manager, Investor Relations |
Biographies
| Name | Description |
|---|---|
James Manuso |
Dr. James S. J. Manuso, Ph.D., MBA, is Chairman of the Board, Chief Executive Officer of Astex Pharmaceuticals, Inc. He served as president, chairman, and chief executive officer from January 2004 to July 2011, as chief executive officer-elect from September 2003 to December 2003 and as a director since February 2001. He is co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and co-founder and managing general partner of The Channel Group LLC. He was also president of Manuso, Alexander & Associates, Inc. Dr. Manuso was a vice president and director of Health Care Planning and Development for The Equitable Companies (now Group Axa), where he also served as an acting medical director. He currently serves on the boards of Novelos Therapeutics, Inc. and privately held KineMed, Inc. Previously, he served on the boards of Merrion Pharmaceuticals Ltd., Inflazyme Pharmaceuticals, Inc., Symbiontics, Inc. (subsequently sold to BioMarin as ZyStor Therapeutics, Inc.), Quark Pharmaceuticals, Inc., Galenica Pharmaceuticals, Inc., and Supratek Pharma, Inc. Dr. Manuso earned a BA with Honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology from the Graduate Faculty of The New School University, a Certificate in Health Systems Management from Harvard Business School and an Executive MBA from Columbia Business School. Dr. Manuso is the author of over 30 chapters, articles and books on topics including health care cost containment and biotechnology company management. Dr. Manuso serves on the Board of Directors of the Biotechnology Industry Organization (BIO) and its Health Section Governing Board. He previously served as vice president and a member of the Board of Trustees of the Greater San Francisco Bay Area Leukemia & Lymphoma Society. |
Harren Jhoti |
Dr. Harren Jhoti, Ph.D., is President, Director of Astex Pharmaceuticals, Inc. He co-founded Astex Therapeutics Limited in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as "Chemistry World Entrepreneur of the Year" for 2007. He has published widely including in journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served as a non-executive director of Iconix Inc. and currently serves on the board of the BIA, the UK BioIndustry Association. Before founding Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989. |
Peter Fellner |
Dr. Peter J. Fellner, Ph.D., is Independent Vice Chairman of the Board of Astex Pharmaceuticals, Inc. Previously he served as chairman of Astex Therapeutics Limited from 2002 through July 2011. He also serves as chairman of Consort Medical plc, Optos plc, Biotie Therapies Corp and Vernalis plc. In addition, he is a director of the global biopharmaceutical company UCB SA, and a member of the Novo A/S Advisory Group. He has served as chairman of several other life science companies, including Acambis plc and Premier Research Group plc, until they each were sold during 2008. He was previously chairman of Celltech Group plc, one of Europe's biotechnology companies until its acquisition in 2004, having served as its CEO from 1990 to 2003. Before joining Celltech, Dr. Fellner served as CEO of Roche UK, from 1986 to 1990. From 1984 to 1986 he was director of the Roche UK Research Centre. |
Michael Molkentin |
Mr. Michael Molkentin is Chief Financial Officer, Corporate Secretary of Astex Pharmaceuticals, Inc. Prior to joining the Company, Mr. Molkentin served as interim chief financial officer at Aradigm Corporation from May 2000 to September 2002. From January 1995 to April 2000, Mr. Molkentin served as division controller for Thermo Finnigan Corporation, a subsidiary of Thermo Electron (now Thermo Fisher Scientific). Mr. Molkentin served in a variety of financial management positions with technology companies, including field controller of Vanstar Corporation, controller of Republic Telcom Systems, Inc. and corporate controller of Computer Automation, Inc. Mr. Molkentin is a CPA and received a BBA in accounting from Bernard M. Baruch College in New York City, New York. |
Mohammad Azab |
Dr. Mohammad Azab, M.D., M.Sc., MBA, is Chief Medical Officer of Astex Pharmaceuticals, Inc. He joined the Company as chief medical officer in July 2009. He possesses more than 20 years of experience in worldwide drug development, clinical research, and medical affairs, resulting in eight approved drugs, including six in oncology. Most recently, he was president and chief executive officer of Intradigm Corporation, a privately held company in Palo Alto, CA developing siRNA cancer therapeutics. Previously, Dr. Azab served as executive vice president of research and development, and chief medical officer of Vancouver, British Columbia-based QLT Inc., where he led clinical development for now-approved drugs in oncology, gastro-intestinal, and ophthalmologic indications. He also served as oncology drug team leader at UK-based Zeneca Pharmaceuticals, now Astra Zeneca, where he held responsibilities in global clinical development and regulatory submissions. In this capacity, he managed the development of drugs for prostate, breast, colorectal, and lung cancer indications. Before Zeneca, Dr. Azab was an international medical manager in oncology at Sanofi Pharmaceuticals, now Sanofi-Aventis, in Gentilly, France. Dr. Azab received his medical degree in 1979 from Cairo University. He practiced as a medical oncologist and received post-graduate training and degrees in oncology research and statistics from the University of Paris-Sud and the University of Pierre and Marie Curie in France. He has published more than 100 medical papers and abstracts. He is an active member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, and the American Society of Hematology. Dr. Azab received an MBA, with Distinction, from the Richard Ivey School of Business, University of Western Ontario. |
Martin Buckland |
Dr. Martin Buckland, D.Phil., MBA, is Chief Business Officer of Astex Pharmaceuticals, Inc. Previously, Dr. Buckland served as chief business officer of Astex Therapeutics Limited since September 2004 and was appointed to its board of directors in July 2008. He has more than 30 years of commercial and business development experience in the pharmaceutical industry and joined Astex Therapeutics Limited from Elan Pharmaceuticals, where he previously held the position of vice president of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech. He has a BA in Chemistry and a D.Phil. from the University of Oxford, and an MBA from the Open Business School. |
Walter Lack |
Mr. Walter J. Lack is Lead Independent Director of Astex Pharmaceuticals, Inc. Mr. Lack is managing partner of Engstrom, Lipscomb & Lack, a Los Angeles, California law firm that he founded in 1974. Mr. Lack has acted as a special arbitrator for the Superior Court of the State of California since 1976 and for the American Arbitration Association since 1979. He is a member of the International Academy of Trial Lawyers and an Advocate of the American Board of Trial Advocates. He received his B.A. from Loyola Marymount University where he is a long standing member of the Board of Regents. He received his J.D. from Loyola Law School in Los Angeles. |
Charles Casamento |
Mr. Charles J. Casamento is Independent Director of Astex Pharmaceuticals, Inc. Mr. Casamento is currently executive director and principal of The Sage Group. Mr. Casamento was the president and CEO of Osteologix, Inc., from 2004 through 2007. From 1999 through 2004, he served as chairman of the board, president and CEO of Questcor Pharmaceuticals, Inc. Mr. Casamento formerly served as RiboGene, Inc.'s president, CEO and chairman of the board from 1993 through 1999 until it merged with Cypros to form Questcor. In 1989 he co-founded and later took public, Interneuron Pharmaceuticals (Indevus). He was senior vice president and general manager for Pharmaceuticals and Biochemicals at Genzyme from 1985 through 1989 while it was an early stage venture backed company and was there at the time Genzyme was taken public. Mr. Casamento has also held senior management positions at American Hospital Supply Corp., where he was vice president of business development and strategic planning for the Critical Care Division; Johnson & Johnson, Hoffmann-LaRoche, Inc. and Novartis Inc. Mr. Casamento also serves on the boards of directors of International Stem Cell Corporation, and VIVUS, Inc. During his career he has served, at various times, on a total of nine boards of public biotechnology/pharmaceutical companies. He is a member of the Fordham University Science Council. He was previously Vice Chairman of The Catholic Medical Mission Board, a international not for profit organization providing health care services to third world countries. He holds a bachelor's degree in Pharmacy from Fordham University and an M.B.A from Iona College and was originally licensed to practice pharmacy in the states of New York and New Jersey. |
Thomas Girardi |
Mr. Thomas V. Girardi is Independent Director of Astex Pharmaceuticals, Inc. Mr. Girardi is senior partner of Girardi & Keese, a law firm specializing in business litigation, where he has worked since 1964. Mr. Girardi has served as national president and Los Angeles chapter president of the American Board of Trial Advocates, has also served as president of the International Academy of Trial Lawyers, from 2005 to 2006, and is a member of the Inner Circle of Advocates, American Board of Professional Liability Lawyers, International Society of Barristers, and American Trial Lawyers Association. Mr. Girardi is also a member of the board of directors of Boyd Gaming, Inc. He received his B.S. from Loyola Marymount University, his J.D. from Loyola Law School, and an L.L.M. from New York University. |
Allan Goldberg |
Dr. Allan R. Goldberg, Ph.D., is Independent Director of Astex Pharmaceuticals, Inc. Dr. Goldberg is currently chief executive officer and president of Avacyn Pharmaceuticals, Inc. He is a co-founder and also serves as advisory partner at The Channel Group LLC. In that capacity, he also served as interim president of Phage Pharmaceuticals, Inc. from April 2010 to April 2011. Prior to his affiliation with TCG, Dr. Goldberg co-founded PrimeTech Partners, a venture management partnership whose purpose was to create, finance and develop biomedical companies. From 1989 to 1997, Dr. Goldberg held various senior management positions, including chief scientific officer, chairman and chief executive officer at Innovir Laboratories, Inc., a NASDAQ-listed biotechnology company he co-founded. He was a director and co-founder of ZyStor Therapeutics, Inc., a Milwaukee-based biotechnology company that was purchased in August 2010 by BioMarin Pharmaceutical Inc. In addition, he also was on the board of directors of LCT BioPharma Inc., the U.S. subsidiary of Living Cell Technologies Limited (ASX:LCT). He was a co-founder and a board member of Lesanne Life Sciences, LLC. Prior to founding Innovir, Dr. Goldberg was a professor of virology and a member of the faculty of The Rockefeller University from 1971 to 1989. Dr. Goldberg has served as a consultant to several pharmaceutical companies as well as numerous private and public academic institutions. He earned a B.A. from Cornell University and a Ph.D. in Biochemistry/Biology from Princeton University, and was a postdoctoral fellow at Albert Einstein College of Medicine. |
Timothy Haines |
Mr. Timothy Haines is Independent Director of Astex Pharmaceuticals, Inc. He has been a partner at Abingworth LLP, a life science and healthcare private investment firm, since 2005. Prior to this, Mr. Haines was chief executive of Astex Therapeutics Limited. Mr. Haines was with Astex Therapeutics Limited for more than five years. Previously, he was chief executive of two divisions of the publicly listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other senior management positions in the United States and Europe. Current and past board positions include Astex Therapeutics Limited, Fovea, Pixium Vision, KSpine, Lombard Medical Technologies, PowderMed, Stanmore Implants and XCounter. Mr. Haines has a B.Sc. from Exeter University and an M.B.A. from INSEAD. He is a former director of the Biotechnology Industry Association and currently sits on the Venture Committee of the British Venture Capital Association. |
Ismail Kola |
Dr. Ismail Kola, Ph.D., is Independent Director of Astex Pharmaceuticals, Inc. He is executive vice president and president, New Medicines at UCB S.A. Dr. Kola joined UCB from Schering-Plough Corporation where he was senior vice president, Discovery Research and Early Clinical Research & Experimental Medicine at Schering-Plough Research Institute and chief scientific officer, Schering-Plough Corporation. Prior to Schering-Plough, Dr. Kola held senior positions at Merck, as senior vice president and site head, Basic Research, and at Pharmacia Corporation where he was vice president, research and global head, Genomics Science and Biotechnology with Pharmacia Corporation, and served as a consultant to SmithKline Beecham Pharmaceuticals, and as a member of their Genomics Advisory Board. Dr. Kola holds adjunct professorships of medicine at Washington University and at Monash University Medical School; a foreign adjunct professorship at The Karolinska Institute; and is a William Pitt Fellow at Pembroke College, Cambridge University, U.K. Dr. Kola has a Ph.D. in Medicine from the University of Cape Town, South Africa. |
Susanna Chau |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
James Manuso |
1,734,910 |
Harren Jhoti |
1,421,150 |
Peter Fellner |
-- |
Michael Molkentin |
1,055,020 |
Mohammad Azab |
1,475,380 |
Martin Buckland |
1,041,550 |
Walter Lack |
-- |
Charles Casamento |
-- |
Thomas Girardi |
-- |
Allan Goldberg |
-- |
Timothy Haines |
-- |
Ismail Kola |
-- |
Susanna Chau |
-- |
As Of 30 Dec 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
James Manuso |
1,718,000 | 273,650 |
Harren Jhoti |
33,484 | 33,779 |
Peter Fellner |
0 | 0 |
Michael Molkentin |
130,000 | 9,500 |
Mohammad Azab |
0 | 0 |
Martin Buckland |
0 | 0 |
Walter Lack |
0 | 0 |
Charles Casamento |
0 | 0 |
Thomas Girardi |
0 | 0 |
Allan Goldberg |
0 | 0 |
Timothy Haines |
0 | 0 |
Ismail Kola |
0 | 0 |
Susanna Chau |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
JHOTI HARREN |
16,084 | $0.00 |
JHOTI HARREN |
16,084 | $0.00 |
GIRARDI THOMAS V |
75,000 | $4.03 |
MANUSO JAMES S J |
29,500 | $5.84 |
MANUSO JAMES S J |
29,500 | $4.03 |
CASAMENTO CHARLES J |
10,000 | $2.01 |
CASAMENTO CHARLES J |
28,500 | $4.03 |
CASAMENTO CHARLES J |
5,500 | $5.91 |
CASAMENTO CHARLES J |
65,500 | $5.87 |
CASAMENTO CHARLES J |
32,500 | $2.10 |
MANUSO JAMES S J |
38,000 | $5.87 |
MANUSO JAMES S J |
38,000 | $4.03 |
CASAMENTO CHARLES J |
30,000 | $0.00 |
MOLKENTIN MICHAEL |
7,500 | $1.65 |
CASAMENTO CHARLES J |
10,000 | $2.01 |
CASAMENTO CHARLES J |
10,000 | $1.98 |
CASAMENTO CHARLES J |
10,000 | $1.98 |
GIRARDI THOMAS V |
40,000 | $2.46 |
JHOTI HARREN |
10,000 | $4.25 |
CASAMENTO CHARLES J |
14,000 | $4.27 |
CASAMENTO CHARLES J |
14,000 | $2.46 |
MANUSO JAMES S J |
40,000 | $4.40 |
MANUSO JAMES S J |
40,000 | $2.46 |
LACK WALTER JOHN |
2,500 | $3.97 |
LACK WALTER JOHN |
10,000 | $2.92 |

